EyeCell™ Skaphor TM Model
Regular Price$2,081.00
Advanced Bioelectric and Neuro-Visual Stimulation for Vision Wellness
EyeCell™ is Lionheart Health’s proprietary bioelectric vision wellness program designed for use with the Skaphor™ Vision Revival platform. It combines programmed bioelectric signals with optical light stimulation and neuro-visual protocols to support visual wellness. The program is intended to address concerns such as eye fatigue and digital eye strain, with its broader regenerative applications remaining investigational.
We accept
About EyeCell™ Skaphor TM Model
EyeCell™ is a multi-modality vision wellness program developed to work with the Skaphor™ platform. It incorporates proprietary bioelectric signal programming and optical stimulation intended to interact with the visual system.
The program’s research framework references biological signaling pathways associated with cellular maintenance, neurovascular function, tissue repair, and healthy aging. These include SDF-1, PDGF, Klotho, Sestrins, Sirtuins, and IGF-1, alongside additional pathways under investigation. These mechanisms are part of the program’s proposed scientific rationale and should not be interpreted as proof that the device increases specific proteins or regenerates damaged eye tissue in humans.
Key Highlights
- Multi-Modality Vision Wellness: Combines bioelectric microcurrent, micropulse optical light, and neuro-visual stimulation.
- Designed for the Skaphor™ Platform: Developed for integration with Lionheart Health’s Skaphor™ Vision Revival system.
- Digital Eye Strain Support: Marketed for eye fatigue and discomfort associated with prolonged screen use.
- Proprietary Signal Programming: Incorporates programmed bioelectric signal sequences inspired by biological pathways involved in cellular and tissue function.
- Neuro-Visual Stimulation: Designed to engage the visual system through structured stimulation protocols.
- Investigational Regenerative Pathways: References SDF-1, PDGF, Klotho, Sestrins, Sirtuins, IGF-1, and other signaling pathways being explored in research.
- Non-Invasive Sessions: Designed for use without surgery or invasive procedures.
- Research-Informed Development: The manufacturer reports small-scale pilot evaluations at five clinical locations in the United States.
Additional Details
Biological Pathways Under Investigation
EyeCell™ references several biological pathways in its proposed approach to vision wellness. Their roles in research include:
- SDF-1 and PDGF: Studied for their involvement in cell signaling, tissue repair, and cellular migration.
- Klotho: Investigated for its relationship with healthy aging, oxidative stress, and cellular resilience.
- Sestrins and Sirtuins: Associated with cellular stress responses, metabolic regulation, and mitochondrial function.
- IGF-1: Involved in cell growth, maintenance, and signaling.
- VEGF, eNOS, and HIF-1α: Studied in relation to vascular function and oxygen delivery.
- BDNF, GDNF, and NGF: Investigated for their roles in neuronal function and survival.
- Apelin, GDF10, and GDF11: Explored in research involving vascular function, tissue signaling, and neural repair.
- COL17A1, Tropoelastin, BMP-9, and OPG: Associated with structural tissue integrity and vascular biology.
These are research areas referenced by the manufacturer, not established clinical outcomes of the EyeCell™ program. The presence of a pathway in the product’s proposed signal library does not establish that the device activates it in a clinically meaningful way.
Clinical Evaluation and Reported Outcomes
Lionheart Health reports that small-scale pilot studies conducted at five U.S. clinical locations found measurable visual-function improvements in approximately four out of five participants. The manufacturer also describes reported changes in visual clarity, contrast sensitivity, or functional vision.
These results should be treated as preliminary manufacturer-reported findings unless supported by independently reviewed study publications. Study design, participant numbers, control groups, measurement methods, and longer-term follow-up are important when assessing the strength of the evidence. Individual results may vary, and these reports do not establish effectiveness for treating eye disease.
Important Safety and Regulatory Information
EyeCell™ is not currently cleared to treat eye diseases, according to the supplied product information. The manufacturer states that medical treatment applications are limited to appropriately approved clinical research settings with informed patient consent.
The program should not replace an eye examination, prescribed treatment, or professional care for vision changes. People with persistent eye discomfort, sudden changes in vision, or diagnosed eye conditions should consult an ophthalmologist before using a vision stimulation device. Confirm the platform’s current regulatory status, intended use, and safety instructions with the manufacturer before purchase or use.